Clinigen To Test U.K. Investors' Appetite For A Pharma Company IPO
This article was originally published in The Pink Sheet Daily
A U.K. supplier of drugs for clinical trials and fledgling specialty pharma company, Clinigen Group, has announced its intention to test U.K. investors' appetite for a pharmaceutical company IPO, with a listing and institutional fundraising on AIM, part of the London Stock Exchange.
You may also be interested in...
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer are helping to fund a public-private partnership aimed at improving the primary care health infrastructure in Africa; the collaboration will also exploit the companies’ experience providing therapies and using digital and web-enabled technologies.